F 18-fluoroazomycin arabinoside
Trade name: faza
Small moleculeexperimentalImaging agent
Faza is a small town on the North coast on Pate Island, within the Lamu Archipelago in Kenya's former Coast Province. — Wikipedia
Clinical trial activity
13 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT00323076)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Adenosquamous · Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Chordoma · Phase 2
- Colorectal Neoplasms · Early Phase 1
- Neoplasms · Early Phase 1
- Neuroendocrine Tumors · Phase 1/Phase 2
- Pancreatic Neoplasms · Early Phase 1
- Rhabdomyosarcoma · Phase 1
- Sarcoma · Phase 1
- Tongue Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFaza ↗
Also known as
- (18f)-1-alpha-d-(2-deoxy-2-fluoroarabinofuranosyl)-2-nitroimidazole
- (18f)faza
- (18f)-faza
- 18f faza
- 18f faza
- 18f-faza
- 18f-faza
- 18f-faza
- (18f)fluoro-azomycinarabino-furanoside
- (18f)fluoroazomycinarabinoside
- 18f fluoroazomycin arabinoside
- 18f fluoroazomycin arabinoside
- 18f-fluoroazomycin arabinoside
- 18f-fluoroazomycin arabinoside
- 18f-fluoroazomycin arabinoside
- faza
- faza
- fluoroazomycinarabinoside
- fluoroazomycin arabinoside
- fluoroazomycin arabinoside
- fluoroazomycin arabinoside
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04395469 | N/A | Aug 31, 2020 | University of Toronto |
| NCT03418818 | N/A | Mar 27, 2018 | University of Toronto |
| NCT03257150 | N/A | Sep 22, 2017 | University of Toronto |
| NCT03168737 | Early Phase 1 (Phase 1) | Jul 1, 2017 | University of Texas at Houston |
| NCT03054792 | Phase 1 | Jun 1, 2017 | University of Toronto |
| NCT03181035 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | University of Toronto |
| NCT02802969 | Phase 2 | Jul 22, 2016 | Curie Institute |
| NCT02394652 | Phase 2 | May 1, 2015 | University of Toronto |
| NCT02701699 | N/A | Dec 1, 2014 | University of Toronto |
| NCT02496832 | N/A | Nov 1, 2014 | Merck, University of Toronto |
| NCT01567800 | N/A | Apr 30, 2012 | University of Toronto |
| NCT00771381 | Phase 2 | Nov 1, 2008 | University of Alberta, University of Calgary |
| NCT00323076 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2004 | University of Alberta, University of Calgary |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Toronto | Academic/Hospital | 9 | 9 | 3 | 2012 |
| University of Alberta | Academic/Hospital | 2 | 0 | 1 | 2004 |
| University of Calgary | Academic/Hospital | 2 | 2 | 1 | 2004 |
| Curie Institute | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Merck | For profit | 1 | 0 | 1 | 2014 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2017 |
6 organizations
Page 1 / 1